Hemab Therapeutics (NASDAQ:COAG) Shares Gap Up – Time to Buy?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) shares gapped up prior to trading on Tuesday. The stock had previously closed at $30.07, but opened at $32.16. Hemab Therapeutics shares last traded at $33.03, with a volume of 11,407 shares changing hands.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Rodman & Renshaw initiated coverage on Hemab Therapeutics in a report on Monday, October 12th. They issued a “buy” rating and a $56.00 price target on the stock. Weiss Ratings cut Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 25th. JPMorgan Chase & Co. began coverage on Hemab Therapeutics in a report on Thursday, October 15th. They set an “overweight” rating and a $70.00 price objective for the company. Jefferies Financial Group lifted their target price on Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, HC Wainwright lifted their target price on Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $54.71.

Hemab Therapeutics Price Performance

The business’s 50 day simple moving average is $40.52. The firm has a market cap of $1.55 billion and a PE ratio of -1.34.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, analysts expect that Hemab Therapeutics Holdings, Inc. will post -3.10 EPS for the current year.

Institutional Trading of Hemab Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp acquired a new position in Hemab Therapeutics during the second quarter valued at approximately $2,825,000. Citadel Advisors LLC bought a new position in Hemab Therapeutics in the second quarter valued at approximately $19,226,000. Opaleye Management Inc. bought a new position in Hemab Therapeutics in the second quarter valued at approximately $1,750,000. Braidwell LP acquired a new position in shares of Hemab Therapeutics during the 2nd quarter worth approximately $5,877,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Hemab Therapeutics during the 2nd quarter worth approximately $688,000.

Hemab Therapeutics Company Profile

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.